Business
Avicanna Announces Medical Cannabis Real World Evidence Results and Publication
Prospective observational study reports improvements in pain-related outcomes, mental health measures, and quality of life among patients using physician-authorized medical cannabis in the Canadian Journal of PainTORONTO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, today announced the pub
About this update from Avicanna Inc
[{"type":"image","alt":"Avicanna Inc.","displaySize":"","headline":null,"caption":"Avicanna Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/1c68da9c20a644cdc756241b8ad53506"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vToBXKkzxq5ehGv_5f_3zA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1c68da9c20a644cdc756241b8ad53506","width":300,"height":300}},"lazy":false},{"type":"text","content":"Prospective observational study reports improvements in pain-related outcomes, mental health measures, and quality of life among patients using physician-authorized medical cannabis in the Canadian Journal of Pain","length":213,"tagName":"p"},{"type":"text","content":"TORONTO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, today announced the publication of results from an investigator-led Medical Cannabis Real-World Evidence (MCRWE) study conducted through the MyMedi.ca platform. The study led by Dr. Hance Clarke, Director of Pain Services at University Health Network (UHN), and has been published in the peer-reviewed Canadian Journal of Pain.","length":591,"tagName":"p"},{"type":"text","content":"The prospective, observational study evaluated patient-reported outcomes among individuals with chronic pain receiving physician-authorized medical cannabis in routine clinical practice. The study reflects a health-care provider-supervised model of medical cannabis use and was supported by multiple clinicians and medical institutions across Canada. The study was led by Dr. Hance Clarke at the University Health Network (UHN) and supported by several other clinicians and medical institutions.","length":495,"tagName":"p"},{"type":"text","content":"“While the term ‘medical cannabis’ is widely used, this study specifically evaluated outcomes among patients using medical cannabis under the supervision of a health-care provider,” said Dr. Hance Clarke, Principal Investigator and Clinician at UHN. “Among chronic pain patients who remained on an authorized medical cannabis product at six months, improvements were observed in pain s...